Literature DB >> 27048653

A New STAT3-binding Partner, ARL3, Enhances the Phosphorylation and Nuclear Accumulation of STAT3.

Sumihito Togi1, Ryuta Muromoto1, Koki Hirashima1, Yuichi Kitai1, Taichiro Okayama1, Osamu Ikeda1, Naoki Matsumoto1, Shigeyuki Kon1, Yuichi Sekine1, Kenji Oritani2, Tadashi Matsuda3.   

Abstract

Signal transducer and activator of transcription 3 (STAT3) is involved in cell proliferation, differentiation, and cell survival during immune responses, hematopoiesis, neurogenesis, and other biological processes. STAT3 activity is regulated by a variety of mechanisms, including phosphorylation and nuclear translocation. To clarify the molecular mechanisms underlying the regulation of STAT3 activity, we performed yeast two-hybrid screening. We identified ARL3 (ADP-ribosylation factor-like 3) as a novel STAT3-binding partner. ARL3 recognizes the DNA-binding domain as well as the C-terminal region of STAT3 in vivo, and their binding was the strongest when both proteins were activated. Importantly, small interfering RNA-mediated reduction of endogenous ARL3 expression decreased IL-6-induced tyrosine phosphorylation, nuclear accumulation, and transcriptional activity of STAT3. These results indicate that ARL3 interacts with STAT3 and regulates the transcriptional activation of STAT3 by influencing its nuclear accumulation of STAT3.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  STAT3; gene transcription; nuclear translocation; protein phosphorylation; signal transduction

Mesh:

Substances:

Year:  2016        PMID: 27048653      PMCID: PMC4900265          DOI: 10.1074/jbc.M116.724849

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

1.  Interactions of STAP-2 with Brk and STAT3 participate in cell growth of human breast cancer cells.

Authors:  Osamu Ikeda; Yuichi Sekine; Akihiro Mizushima; Misa Nakasuji; Yuto Miyasaka; Chikako Yamamoto; Ryuta Muromoto; Asuka Nanbo; Kenji Oritani; Akihiko Yoshimura; Tadashi Matsuda
Journal:  J Biol Chem       Date:  2010-10-07       Impact factor: 5.157

Review 2.  Negative regulation of cytokine signaling pathways.

Authors:  H Yasukawa; A Sasaki; A Yoshimura
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

3.  Arl2 and Arl3 regulate different microtubule-dependent processes.

Authors:  Chengjing Zhou; Leslie Cunningham; Adam I Marcus; Yawei Li; Richard A Kahn
Journal:  Mol Biol Cell       Date:  2006-03-08       Impact factor: 4.138

Review 4.  Intracellular signaling pathways regulating pluripotency of embryonic stem cells.

Authors:  Keisuke Okita; Shinya Yamanaka
Journal:  Curr Stem Cell Res Ther       Date:  2006-01       Impact factor: 3.828

5.  Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality.

Authors:  K Takeda; K Noguchi; W Shi; T Tanaka; M Matsumoto; N Yoshida; T Kishimoto; S Akira
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

6.  Functional involvement of Daxx in gp130-mediated cell growth and survival in BaF3 cells.

Authors:  Ryuta Muromoto; Makoto Kuroda; Sumihito Togi; Yuichi Sekine; Asuka Nanbo; Kazuya Shimoda; Kenji Oritani; Tadashi Matsuda
Journal:  Eur J Immunol       Date:  2010-11-11       Impact factor: 5.532

7.  STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3.

Authors:  Ling Liu; Kevin M McBride; Nancy C Reich
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-26       Impact factor: 11.205

8.  ADP-ribosylation factor (ARF)-like 3, a new member of the ARF family of GTP-binding proteins cloned from human and rat tissues.

Authors:  M M Cavenagh; M Breiner; A Schurmann; A G Rosenwald; T Terui; C Zhang; P A Randazzo; M Adams; H G Joost; R A Kahn
Journal:  J Biol Chem       Date:  1994-07-22       Impact factor: 5.157

9.  STAP-2/BKS, an adaptor/docking protein, modulates STAT3 activation in acute-phase response through its YXXQ motif.

Authors:  Mayu Minoguchi; Shigeru Minoguchi; Daisuke Aki; Akiko Joo; Tetsuya Yamamoto; Taro Yumioka; Tadashi Matsuda; Akihiko Yoshimura
Journal:  J Biol Chem       Date:  2003-01-22       Impact factor: 5.157

Review 10.  STATs in cancer inflammation and immunity: a leading role for STAT3.

Authors:  Hua Yu; Drew Pardoll; Richard Jove
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

View more
  6 in total

Review 1.  ARL3, a small GTPase with a functionally conserved role in primary cilia and immune synapses.

Authors:  Laura Powell; Youhani H Samarakoon; Shehab Ismail; John A Sayer
Journal:  Small GTPases       Date:  2019-12-18

2.  Characterization of a novel RP2-OSTF1 interaction and its implication for actin remodelling.

Authors:  Rodanthi Lyraki; Mandy Lokaj; Dinesh C Soares; Abigail Little; Matthieu Vermeren; Joseph A Marsh; Alfred Wittinghofer; Toby Hurd
Journal:  J Cell Sci       Date:  2018-02-20       Impact factor: 5.285

3.  Deciphering the Role of Emx1 in Neurogenesis: A Neuroproteomics Approach.

Authors:  Firas H Kobeissy; Katharina Hansen; Melanie Neumann; Shuping Fu; Kulin Jin; Jialing Liu
Journal:  Front Mol Neurosci       Date:  2016-10-17       Impact factor: 5.639

Review 4.  STAT3 Interactors as Potential Therapeutic Targets for Cancer Treatment.

Authors:  Federica Laudisi; Fabio Cherubini; Giovanni Monteleone; Carmine Stolfi
Journal:  Int J Mol Sci       Date:  2018-06-16       Impact factor: 5.923

5.  Epidermal growth factor promotes proliferation and maintains multipotency of continuous cultured adipose stem cells via activating STAT signal pathway in vitro.

Authors:  Guihai Ai; Xiaowen Shao; Meng Meng; Liwen Song; Jin Qiu; Yi Wu; Jianhong Zhou; Jiajing Cheng; Xiaowen Tong
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

6.  ARL3 is downregulated and acts as a prognostic biomarker in glioma.

Authors:  Yulin Wang; Weijiang Zhao; Xin Liu; Gefei Guan; Minghua Zhuang
Journal:  J Transl Med       Date:  2019-06-24       Impact factor: 5.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.